Impact of prescription-free access to sexually transmitted infection screening tests in medical-biological laboratories: cross-sectional analysis of data from clinical laboratories in France.

This cross-sectional analysis of French clinical laboratory data from 2025–2026 demonstrates that the 2024 reform enabling prescription-free STI screening significantly increased testing uptake among young men and improved the detection of bacterial infections like Chlamydia, while prescription-based access remained crucial for identifying viral and chronic infections.

The Gist

Imagine the healthcare system as a massive, busy train station. For years, if you wanted to get tested for sexually transmitted infections (STIs), you had to follow a very specific route: first, you had to buy a "ticket" (a doctor's prescription) from a station master (your GP), and then you could board the train to the testing lab.

In September 2024, France decided to build a new, express "walk-up" platform right at the station entrance. You could now hop on the testing train without needing a ticket or a ticket-master's permission first. This is called Prescription-Free Access (PFA).

This study is like a traffic report analyzing who used this new express platform versus the old ticketed route, and how many "passengers" (people) were found to have infections.

Here is the breakdown of what they found, using simple analogies:

1. Who took the Express Train?

The new "walk-up" platform was a huge hit with young adults (ages 20–39) and men.

• The Analogy: Think of the old system as a formal dinner party where you need an invitation (a doctor's note). The new system is like a "pay-what-you-can" food truck right outside the club. Young people and men, who often find formal parties intimidating, expensive, or just too much hassle, flocked to the food truck.
• The Result: About 28% of all people getting tested used this new, easy method. It successfully reached people who usually avoid doctors.

2. What "Luggage" Did They Find? (The Infections)

The researchers looked at what kind of "luggage" (infections) people were carrying. They found a clear pattern based on how people got tested.

• The "Fresh" Infections (Chlamydia & Gonorrhea):

  • The Analogy: These are like fresh, fast-moving viruses. They spread quickly among young, active crowds.
  • The Finding: The new "walk-up" platform was excellent at catching these. In fact, it found more cases of Chlamydia than the old system did. It's like the food truck caught the hungry, young crowd that the formal dinner party missed.
  • The Gender Twist: Interestingly, young women using the new system were found to have more of these infections than women using the old system. This suggests the new system helped women who were worried or shy about going to a doctor finally get tested.

• The "Old" or "Heavy" Infections (Syphilis, Hepatitis B, HIV):

  • The Analogy: These are like heavy, slow-moving cargo or old, rusted machinery. They often affect older people or those with long-term health issues who are already seeing doctors regularly.
  • The Finding: The old "ticketed" system (going through a doctor) was still the best way to find these. Most people with these infections were found via the traditional route.
  • Why? People with these conditions often have other health needs that require a doctor's visit anyway. The "walk-up" platform didn't attract as many people with these specific, chronic issues.

3. The "Double Trouble" (Co-infections)

The study also looked at people carrying two or more infections at once.

• The Finding: It didn't matter which platform you used; the rate of having multiple infections was about the same.
• The Takeaway: Whether you walked in the front door or came with a doctor's note, if you had multiple infections, you were likely to be found. The new system didn't miss the "double trouble" cases.

4. The Big Picture: Two Doors, One House

The most important lesson from this study is that both doors are necessary.

• The New Door (Prescription-Free): This is the "catch-all" net. It's fantastic for catching the young, the busy, and the hesitant. It stops the spread of fast-moving bacterial infections (Chlamydia/Gonorrhea) by getting people tested quickly.
• The Old Door (Doctor's Prescription): This is the "specialist" door. It remains essential for finding chronic viral infections (HIV, Hep B) and for people who need a full medical check-up, not just a test.

The Conclusion

Think of public health like a fire department.

• The new prescription-free access is like a fire truck that can drive right up to a small, fast-spreading kitchen fire (Chlamydia) and put it out immediately because it's so close and easy to reach.
• The old doctor-prescription system is like the heavy-duty fire crew needed to handle a complex, deep-seated structural fire (HIV/Syphilis) that requires a full investigation.

The Verdict: By building the new "walk-up" platform, France didn't replace the old system; they added a powerful new tool. They caught a massive wave of young people who were previously slipping through the cracks, proving that making testing easier saves lives and stops infections from spreading.

Technical Summary

1. Problem Statement

Sexually transmitted infections (STIs) remain a significant global public health burden. Effective control relies on the "Test-and-Treat" paradigm, which requires rapid detection and treatment to interrupt transmission chains. However, traditional screening pathways in France often involve structural and psychological barriers, such as the mandatory requirement for a physician's prescription, limited office hours, and the need for multiple visits. These barriers disproportionately affect high-risk, underserved populations, particularly adolescents, young adults, and men, leading to attrition in the screening continuum and underdiagnosis of asymptomatic infections.

In September 2024, France implemented a national reform allowing Prescription-Free Access (PFA) to STI screening in Medical-Biological Laboratories (MBLs). The study aims to evaluate the real-world impact of this reform by characterizing the demographics of users and comparing the diagnostic yield (positivity rates) between the new PFA modality and the traditional Prescription-Based Access (PBA) modality.

2. Methodology

• Study Design: Cross-sectional analysis of routine laboratory data.
• Data Source: The Cerballiance health data warehouse, covering MBLs across most of metropolitan France (excluding Pays de la Loire, Bretagne, and Martinique).
• Study Period: March 1, 2025, to February 28, 2026. (The first six months post-reform were excluded to avoid transitional coding inconsistencies).
• Population:
  • Initial pool: ~1.46 million subjects.
  • Final study population: 1,008,737 individuals after exclusions for age (<15), missing data, inconsistent test results, or uninterpretable results.
  • Access Modalities: 27.8% accessed via PFA; 72.2% via PBA.
• Screening Protocol:
  • Bacterial STIs (Chlamydia trachomatis, Neisseria gonorrhoeae): Detected via Nucleic Acid Amplification Tests (NAATs) on urogenital, rectal, and pharyngeal specimens.
  • Viral/Bacterial STIs (HIV, HBV, Syphilis): Detected via automated immunoassays on serum. HIV used combined Ab/Ag; Syphilis used treponemal-specific immunoassay (TSI).
• Statistical Analysis:
  • Descriptive and bivariate analyses (Chi-squared, t-tests).
  • Multivariable Logistic Regression: Stratified by sex and adjusted for age and region.
  • Interaction Terms: Included to assess age-specific variations in the association between access modality and positivity.
  • Outcome Measures: Odds Ratios (OR) and adjusted predicted probabilities of positivity for specific STIs and co-infections.

3. Key Contributions

• Large-Scale Real-World Evidence: This is one of the largest studies (over 1 million individuals) evaluating the immediate impact of a national policy shift toward prescription-free STI testing.
• Granular Stratification: The analysis provides a detailed breakdown of positivity rates by access modality, sex, and specific age groups, revealing nuanced differences often masked in aggregate data.
• Pathogen-Specific Insights: The study distinguishes between the detection profiles of acute bacterial STIs (Chlamydia, Gonorrhea) versus chronic/viral infections (HIV, HBV, Syphilis), demonstrating that different access modalities serve complementary epidemiological roles.
• Quantification of Co-infection: The study analyzes co-infection patterns, finding that while access modality does not significantly alter co-infection rates, age remains the strongest predictor.

4. Key Results

• Demographic Shifts:
  • PFA users were significantly more likely to be male (47.4% vs. 36.3% in PBA) and aged 20–39 years.
  • PFA users underwent a higher mean number of tests per individual (2.81 vs. 2.53) and were screened more frequently for HIV and bacterial STIs.
• Positivity Rates by Modality:
  • Chlamydia: PFA showed a higher detection rate overall (4.6% vs. 3.6%).
    • Women: PFA associated with higher odds of positivity (OR 1.23), particularly in the 20–29 age group.
    • Men: PFA showed no overall difference, but significantly lower odds of positivity in men aged 30+ compared to PBA.
  • Gonorrhea: PFA associated with higher positivity in women (OR 1.56) and lower positivity in men (OR 0.76), with the reduction in men becoming more pronounced with age.
  • Syphilis, HBV, and HIV: PBA was associated with significantly higher positivity rates for these infections.
    • Syphilis: 3.4% (PBA) vs. 1.2% (PFA).
    • HBV: 1.3% (PBA) vs. 0.4% (PFA).
    • HIV: 0.3% (PBA) vs. 0.2% (PFA).
    • Interpretation: The PBA pathway captures older populations and those with chronic/long-standing infections, whereas PFA captures younger, acute cases.
• Co-infections: No significant difference in co-infection rates between PFA and PBA. Age was the primary driver, with the 15–19 age group showing the highest co-infection burden.
• Volume Impact: Approximately 26.7% of all confirmed positive bacterial STI cases and 16.6% of syphilis cases were detected via the prescription-free pathway.

5. Significance and Conclusion

• Public Health Impact: The prescription-free reform successfully broadened the screening net, particularly reaching young men and young adults who are historically difficult to engage through traditional physician-mediated pathways.
• Complementary Strategies: The study concludes that PFA and PBA are not mutually exclusive but complementary.
  • PFA is highly effective for detecting acute, bacterial STIs in high-transmission, younger demographics.
  • PBA remains essential for diagnosing chronic viral infections (HIV, HBV) and syphilis, which are more prevalent in older populations or those already engaged in medical care.
• Policy Implication: The findings support the integration of flexible, direct-access testing as a core component of national STI control strategies to reduce transmission chains, while maintaining conventional pathways for comprehensive management of chronic conditions.
• Limitations: The study notes potential selection bias (users of specific lab networks), lack of socioeconomic data, and the exclusion of certain French regions. Additionally, the syphilis data reflects cumulative serological history (past infections) rather than just acute incidence, though reflex testing (VDRL) is noted as a future analysis step.

In summary, the removal of prescription barriers in France has significantly increased STI screening uptake and early detection of bacterial infections among young adults, validating the policy as an effective public health intervention that works in tandem with, rather than replacing, traditional medical pathways.